AbCellera Biologics (ABCL) PT Lowered to $34 at Credit Suisse
Tweet
Share
E-mailGet Alerts ABCL Hot Sheet
Price: $11.38 +3.74%
Rating Summary:
12 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
12 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Credit Suisse analyst Tiago Fauth lowered the price target on AbCellera Biologics (NASDAQ: ABCL) to $34.00 (from $40.00) while maintaining a Outperform rating.
You May Also Be Interested In
- These Have the Market Hot Zone Catalysts and Setups
- Stantec Inc. (STN:CN) (STN) PT Lowered to Cdn$169 at Desjardins
- AbCellera prices $200M public offering of shares and warrants
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
